Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6208320 | 0.98 | LMNA (0.50) | LMNASMN1; SMN2ALDH1A1L3MBTL1POLB | |
| SCHEMBL6208716 | 0.80 | SLC6A4 (0.65) | LMNASMN1; SMN2ALDH1A1L3MBTL1POLB | |
| SCHEMBL6209826 | 0.79 | SLC6A3 (0.58) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL6492041 | 0.79 | SLC6A4 (0.68) | LMNASMN1; SMN2L3MBTL1SLC6A4SLC6A3 | |
| SCHEMBL7573036 | 0.79 | SOAT2 (0.51) | LMNAALDH1A1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL6240339 | 0.78 | SLC6A3 (0.60) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL6231738 | 0.75 | SLC6A3 (0.61) | LMNASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL16823453 | 0.75 | SLC6A4 (0.62) | LMNASMN1; SMN2ALDH1A1L3MBTL1POLB | |
| SCHEMBL6494934 | 0.74 | SLC6A4 (0.63) | LMNASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL6208456 | 0.72 | RORC (0.48) | LMNASMN1; SMN2L3MBTL1POLBSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | US | disclosed |
| EP-1507763-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003097607-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | PPARD, PPARG, PPARA | LMNA 2034/4885SMN1; SMN2 4874/4885ALDH1A1 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.